AMULET vs. WATCHMAN: Appendage Closure Devices, Head to Head

This research was designed to compare the double closure system of the AMULET device with the WATCHMAN (an evidence-backed proven device).

AMULET vs WATCHMAN. Los dispositivos de cierre de orejuela cabeza a cabeza

In that context, to prevent stroke in patients with non-valvular atrial fibrillation, the Amplatzer AMULET device was non-inferior in both safety and efficacy compared with the WATCHMAN. Atrial appendage occlusion in itself improved with AMULET, but with a higher rate of procedure-related complications that decreased with operator experience.

This study randomized 1878 patients with non-valvular atrial fibrillation and increased risk of stroke 1:1 to atrial appendage occlusion with either the AMULET or the WATCHMAN device.

There were two primary endpoints: one for safety (a composite of procedure-related complications, all-cause mortality, or major bleeding at 1 year) and one for efficacy (a composite of ischemic stroke or systemic embolism at 18 months), plus total appendage occlusion at 45 days.

The secondary endpoints were combinations of the aforementioned events.

The AMULET device was non-inferior to the WATCHMAN in the primary efficacy endpoint (14.5% vs. 14.7%; 95% confidence interval: 3.42 to 3.13; p < 0.001 for non-inferiority).

Major bleeding and all-cause mortality were also similar between devices (10.6% vs. 10.0% and 3.9% vs. 5.1%, respectively).


Read also: Asymptomatic Carotid Lesions and Cognitive Impairment: Does Intervention Play a Role?


The AMULET device almost doubled peri-procedural complications (4.5% vs. 2.5%)—primarily due to pericardial effusion and device embolization.

Major bleeding rates were similar in both groups (11.6% vs. 12.3%), while effective atrial appendage occlusion was higher with the AMULET device.

Conclusion

The AMULET atrial appendage occluder device was non-inferior in terms of safety and efficacy to the WATCHMAN device for stroke prevention in patients with non-valvular atrial fibrillation. Periprocedural complications observed with the AMULET decreased with operator experience.

amulet-versus-watchman

Original Title: AMPLATZERTM AMULETTM LEFT ATRIAL APPENDAGE OCCLUDER VERSUS WATCHMANTM DEVICE FOR STROKE PROPHYLAXIS (AMULET IDE): A RANDOMIZED CONTROLLED TRIAL.

Reference: Dhanunjaya Lakkireddy et al. 10.1161/CIRCULATIONAHA.121.057063.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...